Neil Harris Cohen sold $4,818 of CMMB
director at Chemomab Therapeutics Ltd.. 2,409 shares at an average of $2.00, traded Nov 16, 2022, filed Nov 18, 2022.
Score components
- +15RoleDirector
- 0Trade size$5k at market
- +5Share of holdings soldSold 19% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001178913-22-004100, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 16, 2022 | SOpen-market sale American Depositary Shares | -2,409 | $2.00 | $4,818 | 10,000 | Nov 18, 2022 |
| Mar 7, 2022 | AGrant or award Option to Purchase American Depositary Sharesderivative | +6,820 | $0.00 | $0 | 6,820 | Nov 18, 2022 |
| Apr 19, 2021 | AGrant or award Option to Purchase American Depositary Sharesderivative | +11,884 | $0.00 | $0 | 11,884 | Nov 18, 2022 |
| Mar 16, 2021 | AGrant or award Option to Purchase American Depositary Sharesderivative | +688 | $0.00 | $0 | 688 | Nov 18, 2022 |
Related signals
Other insiders at Chemomab Therapeutics Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | CMMBsell Chemomab Therapeutics Ltd. | Neil Harris Cohen director | $6,516 2,304 shares | -7% | |
| 36Weak | CMMBbuy Chemomab Therapeutics Ltd. | George Adi Mor Chief Executive Officer | $20k 9,804 shares | +8% | |
| 68Notable | Chemomab Therapeutics Ltd. | George Adi Mor Chief Scientific Officer | $1.2M 582,023 shares | -90% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.